Table 2.
Primary tumor (T) | |
---|---|
Tx | Primary tumor cannot be assessed |
T0 | No evidence of primary tumor |
Tis | In situ primary tumor |
T1 | Primary tumors less than or equal to 2 cm maximum tumor dimension |
T2 | Primary tumors greater than 2 cm but not more than 5 cm maximum tumor dimension |
T3 | Primary tumors over 5 cm maximum tumor dimension |
T4 | Primary tumor invades bone, muscle, fascia, or cartilage |
| |
Regional lymph nodes (N) | |
| |
Nx | Regional lymph nodes cannot be assessed |
N0 | No regional lymph node metastasis |
cN0 | Nodes negative by clinical exam (no pathologic node exam performed) |
pN0 | Nodes negative by pathologic exam |
N1 | Metastasis in regional lymph node(s) |
N1a | Micrometastasis |
N1b | Macrometastasis |
N2 | In-transit metastasis |
| |
Distant metastasis (M) | |
| |
M0 | No distant metastasis |
M1 | Metastasis beyond regional lymph nodes |
M1a | Metastasis to skin, subcutaneous tissues, or distant lymph nodes |
M1b | Metastasis to lung |
M1c | Metastasis to all other visceral sites |
| |
Anatomic stage/prognostic groups | |
| |
IA | Primary tumor ≤2 cm; regional LN negative by pathologic examinationa |
IB | Primary tumor ≤2 cm; regional LN negative by clinical examination onlyb |
IIA | Primary tumor >2 cm; regional LN negative by pathologic examinationa |
IIB | Primary tumor >2 cm; regional LN negative by clinical examination onlyb |
IIIA | Primary tumor any size; positive micrometastasis in regional LNc |
IIIB | Primary tumor any size; clinically detectable regional LN metastasis and/or in-transit metastasisd |
IV | Primary tumor any size; any distant metastasis |
aNegative sentinel lymph node biopsy (SLNB) or elective lymph node dissection (ELND).
bNo pathologic LN evaluation (SLNB or ELND).
cPositive micrometastasis by SLNB or ELND.
dConfirmed pathologically by biopsy or therapeutic lymph node dissection.
LN: lymph nodes.